Breaking Finance News

Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) target price raised to $26.00, reported today by SunTrust Banks, Inc.

Just yesterday Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) traded 4.23% higher at $13.52. Verona Pharma plc – American Depositary Share’s 50-day average is $13.63 and its two hundred day average is $13.63. The last closing price is down 19.29% from the 200-day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Trading volume was up over the average, with 25,693 shares of VRNA changing hands over the typical 10,176

Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) had its target price raised to $26.00 by SunTrust Banks, Inc. in a report released Monday May 22, 2017. The new target price indicates a possible upside of 0.92% based on the company's last closing price.

Performance Chart

Verona Pharma plc - American Depositary Share (NASDAQ:VRNA)

With a total market value of $0, Verona Pharma plc – American Depositary Share has with a one year low of $11.05 and a one year high of $17.50 .

General Company Details For Verona Pharma plc – American Depositary Share (NASDAQ:VRNA)

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companyÂ’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *